Recently, the Jiangsu Provincial Department of Science and Technology released the "Announcement of Proposed Projects for the 2023 Provincial Science and Technology Plan Special Fund (Key R&D Plan Social Development)", which listed Cetagliptin, a new generation of highly selective DPP-4 inhibitor independently developed by CGeneTech, as a proposed project for the 2023 Jiangsu Provincial Science and Technology Plan Special Fund Biomedical Category.

The Jiangsu Provincial Science and Technology Plan Special Fund is a special fund aimed at addressing the major innovation needs of Jiangsu's economic and social development, supporting various innovative entities in Jiangsu to carry out basic research, tackle key core technologies, construct and operate innovation platforms, and support the construction of a high-level innovation system in the province. It promotes the allocation of scientific and technological resources to be more scientific and efficient, and improves the efficiency of scientific and technological innovation output. At present, there are nearly 6000 biopharmaceutical enterprises in Jiangsu Province. This year, more than 20 innovative products in the biopharmaceutical category were selected as proposed projects through the special fund of the provincial science and technology plan.

The selection of Cetagliptin project this time is based on its continuous innovative achievements in clinical research and development. Cetagliptin adopted a new drug research and development model guided by quantitative pharmacological models when entering the first phase of clinical trials, and pioneered the direct exemption of phase II from phase III clinical trials in the domestic DPP-4 field through quantitative pharmacological models.

At the diabetes Forum of Peking University held in May this year, Professor Ji Linong, the director of the Department of Endocrinology of Peking University People's Hospital, announced the data and results of two phase III clinical trials of Cetagliptin. Low dose can reach the preset end point of the trial, high dose group can also show the safety of the drug very well, and the treatment effect of "quantity" with half power is expected to become the best hypoglycemic drug in the same category. At present, Cetagliptin has submitted an NDA (New Drug Listing Application) to the National Drug Administration and has been accepted.

Professor Hong Tianpei, Vice Chairman of the Endocrinology Branch of the Chinese Medical Association, stated after listening to Professor Ji Linong's report: As a Class 1.1 new drug independently developed by Chinese companies, Cetagliptin has shown us excellent clinical data, especially in exempting Phase II clinical trials and directly entering Phase III clinical trials. What is impressive is that the comparison of the two dose groups demonstrates the advantages of low effective dose and safer safety. We look forward to this product being launched as soon as possible

CGeneTech was founded in Suzhou Industrial Park in 2010 and is a biotechnology company in the commercialization stage. Its core team has decades of experience in the entire lifecycle of international drugs, dedicated to the research and development and industrialization of high-quality and differentiated small molecule innovative drugs. With an integrated drug research and development technology platform and a diversified business perspective, the company has built a rich pipeline of innovative drugs, covering multiple disease fields such as hypoglycemic, anticancer, and autoimmune.